Yezan Munther Haddadin, Director at Outlook Therapeutics, Inc. (OTLK), bought 33,343 shares at $1.27 ($43K) on 2022-10-07, disclosed to the SEC on 2022-10-11.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.29 | 29,743 | $38K | 89.4% |
| 2 | $1.27 | 3,600 | $5K | 10.6% |
| Total | $1.29 avg | 33,343 | $43K | 100% |
| Filing → |
| OTLK | BUY | 2024-03-29 | $22K | — | Filing → |
| OTLK | BUY | 2021-12-02 | $14K | — | Filing → |
| OTLK | BUY | 2021-04-20 | $18K | — | Filing → |